What is the overview of tonsillar squamous cell carcinoma, including recommended investigations and management?

Tonsillar Squamous Cell Carcinoma: Overview, Investigations, and Management

Overview

Tonsillar squamous cell carcinoma (TSCC) is an oropharyngeal malignancy with a high propensity for cervical lymph node metastasis (approximately 69-75% of cases), and HPV-positive disease carries a better prognosis than HPV-negative tumors, though current treatment strategies remain identical for both. 1, 2

Key Epidemiologic and Prognostic Features:

• Occult cervical metastasis occurs in approximately 23-24% of clinically node-negative patients, mandating elective neck treatment 3, 2
• Approximately 50% of patients with locally advanced disease will experience recurrence after primary treatment, most within the first two years 1
• HPV-positive oropharyngeal cancers (identified by p16 immunohistochemistry as a surrogate marker) have superior outcomes but should receive the same treatment intensity as HPV-negative disease, as de-escalation remains investigational 1
• Advanced T classification (T3-4) is the primary independent predictor of worse disease-specific and overall survival 4

---

Investigations

Essential Diagnostic Workup:

• Clinical examination with flexible endoscopy to assess primary tumor extent and bilateral neck involvement 1
• Cross-sectional imaging (CT or MRI) to evaluate tumor depth, bone/soft tissue invasion, and nodal disease 1
• p16 immunohistochemistry on biopsy specimens as a validated surrogate marker for HPV status and prognostic stratification 1
• PD-L1 testing (FDA-approved immunohistochemistry) for patients with recurrent/metastatic disease to guide immunotherapy selection 1
• Baseline FDG-PET/CT for staging in locally advanced disease and to establish a reference for post-treatment surveillance 5

Pre-Treatment Laboratory Testing:

• DPD (dihydropyrimidine dehydrogenase) testing is mandatory before initiating 5-fluorouracil-based chemotherapy 1

---

Management

Early-Stage Disease (T1-T2, N0-N1)

Single-modality treatment with either surgery or radiotherapy is the standard approach for early-stage TSCC, as both provide equivalent locoregional control and survival. 1, 4

Surgical Approach:

• Wide local excision with ≥5 mm margins combined with elective ipsilateral selective neck dissection (levels I-III) is recommended due to the 23-24% risk of occult metastasis 3, 2
• For contralateral cN0 neck: elective treatment is generally not required unless the tumor crosses midline or is poorly differentiated; contralateral occult metastasis occurs in <10% of cases 2
• Tumor tonsillectomy before definitive radiotherapy does not improve outcomes and is not indicated 4

Radiation Therapy Approach:

• IMRT or VMAT to 70 Gy is mandatory for all patients receiving radiotherapy 1
• Radiotherapy alone achieves comparable outcomes to surgery in early-stage disease 4, 6

---

Locally Advanced Disease (T3-T4 or N2-N3)

For locally advanced TSCC, standard treatment options are either primary surgery followed by adjuvant (chemo)radiotherapy OR primary concurrent chemoradiotherapy, with equivalent survival outcomes between approaches. 1, 7, 6

Primary Surgical Strategy:

• En bloc resection of the primary tumor (including mandible or skin if involved) followed by comprehensive ipsilateral neck dissection is the preferred approach for T3/T4 disease 1, 3
• Bilateral neck dissection should be performed for midline-crossing tumors 2
• Postoperative radiotherapy (58-64 Gy) is indicated for: pT3-T4 disease, positive/close margins (≤5 mm), perineural invasion, lymphovascular invasion, >1 involved lymph node, or extracapsular extension 1, 3
• Postoperative concurrent chemoradiotherapy (66 Gy + cisplatin) is mandatory for R1 resection or extracapsular extension, as it improves overall survival compared to RT alone 1
• Timing is critical: postoperative RT/CRT must begin within 6-7 weeks of surgery, with the entire treatment sequence completed within 11 weeks 1

Postoperative Chemotherapy Regimens:

• Standard: Cisplatin 100 mg/m² on days 1,22, and 43 concurrent with RT 1
• Alternative for cisplatin-unsuitable patients: Weekly cisplatin 40 mg/m², carboplatin + 5-FU, cetuximab, or hyperfractionated/accelerated RT without chemotherapy 1

Primary Chemoradiotherapy Strategy:

• Concurrent chemoradiotherapy (70 Gy IMRT/VMAT + cisplatin 100 mg/m² on days 1,22,43) is the standard organ-preservation approach 1
• This approach provides equivalent overall survival and disease-specific survival compared to primary surgery in multiple retrospective series 4, 7, 6, 8
• Hypoxic radiosensitizers increase locoregional control and disease-free survival compared to RT alone 1

Post-Treatment Neck Management:

• Neck dissection is NOT recommended if FDG-PET/CT at 12 weeks post-CRT shows negative findings and normal-sized lymph nodes 1
• However, FDG-PET/CT has a 5% false-negative rate for detecting viable tumor in HPV-associated TSCC/BOTSCC, so clinical judgment remains important 5

---

Recurrent and Metastatic Disease

For recurrent/metastatic TSCC, treatment selection is guided by PD-L1 expression status, prior platinum exposure, and performance status. 1

First-Line Systemic Therapy:

For PD-L1-positive tumors (CPS ≥1):

• Pembrolizumab monotherapy is the standard for patients not requiring rapid tumor shrinkage 1
• Pembrolizumab + platinum/5-FU is recommended when rapid tumor shrinkage is needed 1, 3

For PD-L1-negative tumors:

• Platinum/5-FU/cetuximab (EXTREME regimen) remains the standard first-line therapy 1, 3

Second-Line Systemic Therapy (After Platinum Failure):

• Nivolumab is the preferred agent for patients progressing within 6 months of platinum therapy, providing median OS of 7.5 months versus 5.1 months with chemotherapy 1, 3
• Alternative options: Cetuximab (median OS 5.2-6.1 months), taxanes with or without cetuximab/methotrexate, or TPeX (cisplatin/docetaxel/cetuximab), though the latter lack randomized trial support 1, 3

Salvage Locoregional Treatment:

• Patients with isolated locoregional recurrence should be referred to a tertiary center for multidisciplinary evaluation of salvage surgery or re-irradiation in highly selected cases 1
• Oligometastatic disease (≤2 distant sites) may be considered for curative-intent local/regional treatment after response to systemic therapy 1

---

Multidisciplinary Care Requirements

All treatment decisions must be reviewed by a multidisciplinary tumor board including head-and-neck surgeons, radiation oncologists, medical oncologists, pathologists, radiologists, and supportive care specialists (speech/swallowing, nutrition, psychology) 1, 3

Patients should be treated at high-volume facilities with dedicated head-and-neck oncology expertise to optimize outcomes 1, 3

---

Common Pitfalls and Caveats

• Do not perform tumor tonsillectomy before definitive RT/CRT in the organ-preservation approach, as it does not improve outcomes 4
• Do not omit elective ipsilateral neck treatment in clinically node-negative patients, given the 23-24% occult metastasis rate 3, 2
• Do not delay postoperative RT/CRT beyond 6-7 weeks, as timing significantly impacts locoregional control 1
• Do not rely solely on negative FDG-PET/CT to exclude residual disease post-CRT, as it has a 5% false-negative rate in HPV-associated disease 5
• Do not de-escalate treatment for HPV-positive disease outside of clinical trials, despite its better prognosis 1
• Always test DPD before initiating 5-FU to avoid life-threatening toxicity 1